A study of a new pneumonia vaccine for babies
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests an experimental vaccine that protects against pneumococcal infections, which can cause pneumonia, meningitis, and ear infections. Your baby would get the vaccine as a series of three doses starting at about 2 months of age, followed by a booster around 12–15 months. The goal is to see how safe and how well-tolerated the vaccine is for infants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby should be about 2 months old (between 6 and 13 weeks) at the time of the first dose.
- Your baby should be in good health overall.
- Your baby must have been born at full term (at least 37 weeks) and weigh more than 5.5 pounds at birth.
- Your baby must not have already received a pneumococcal vaccine.
- Your baby should not have any serious immune system problems, major birth defects, or uncontrolled nervous system disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational vaccine that may protect infants against infections caused by a bacteria called Streptococcus pneumoniae, which can cause pneumonia and other serious illnesses. The vaccine is given to healthy babies around 2 months old, and the study will see how well it works and how safe it is.
This study tests a new vaccine to protect infants from pneumococcal disease (a serious bacterial infection). Researchers want to see how well the vaccine works and how safe it is in healthy babies aged 2–6 months.
This study tests a new pneumococcal vaccine (PCV24) for babies ages 2 to 23 months. It aims to see if the vaccine is safe and helps protect against serious infections like pneumonia and meningitis.
This study tests whether a new pneumococcal vaccine (which protects against a serious bacterial infection) is safe in healthy 2-month-old infants. Researchers will watch for side effects and help protect future babies from pneumococcal disease.
This trial tests a new pneumococcal vaccine for babies around 2 months old. It aims to prevent serious infections like pneumonia and meningitis, and may offer protection against more strains than current vaccines.
This study tests a new pneumonia vaccine (PCV13) in healthy infants to see if it works as well as a current vaccine. It compares the immune response and safety of the two vaccines.
Hear when a new Pneumonia, Bacterial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.